CN1795868A - Medication possessing activity of fighting against senium - Google Patents
Medication possessing activity of fighting against senium Download PDFInfo
- Publication number
- CN1795868A CN1795868A CNA2004101004542A CN200410100454A CN1795868A CN 1795868 A CN1795868 A CN 1795868A CN A2004101004542 A CNA2004101004542 A CN A2004101004542A CN 200410100454 A CN200410100454 A CN 200410100454A CN 1795868 A CN1795868 A CN 1795868A
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- activity
- fighting against
- against senium
- low polarity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A medicine with sanility-delaying activity for treating PADAM of man and early climacteric syndrome of woman is prepared from one or more low-polarity ginsenosides without glycosyl on the 20th C site.
Description
Technical field:
The present invention relates to have the medicine of activity of fighting against senium, particularly relate to the listed low polarity ginsenoside of table 1.Described low polarity ginsenoside structurally all belongs to the ginsenoside of sugar based on 20 carbon, has the degraded of antagonism gonadal hormone, improves the activity of gonadal hormone blood plasma level, thereby bring into play antidotal effect.
Background technology:
Radix Ginseng is medicinal in the history in existing thousands of years of China, it has multiple physiology and pharmacological action, as antitumor, enhance immunity, microcirculation improvement, steadily blood pressure, blood sugar regulation, blood fat reducing, calm the nerves, defying age, antitonic, adjusting digestive function, prevention of digestive tract ulcers, raising quality of life, hypermnesis and learning capacity etc.But for many years, it is not clear that the multiple pharmacologically active of Radix Ginseng faces effective ingredient always, the query that mechanism is unclear.
Generally acknowledge that at present the ginsenoside is the effective ingredient of Radix Ginseng, still, the natural ginseng saponin is water soluble compound, by the ability extreme difference of intestinal absorption, is difficult to into blood performance drug action.The medicinal forms of Radix Ginseng has bright ginseng, Radix Ginseng and Radix Ginseng Rubra, and three's relation is that bright ginseng obtains Radix Ginseng through the room temperature drying, and is Radix Ginseng Rubra through steaming after drying.Use experience and study of pharmacy show that the drug effect of Radix Ginseng Rubra is higher than Radix Ginseng and bright ginseng.Unique drug effect of modern study proof Radix Ginseng Rubra has benefited from wherein containing distinctive Rg
2, Rg
3, Rh class, Rk class and natural trace such as polyacetylene compound such as Panaxynol or rare composition.In addition, foreign study finds that natural ginseng saponin intestinal metabolite is the real pharmacological component of Radix Ginseng.
In mid-aged population, with advancing age, in various degree unusual all easily takes place in all links of human hypothalamic-hypophysis-gonad axis, and man's testosterone takes place and partly lacks (partical androgendeficiency in aging male, PADAM in the male.Sometimes also claim the male menopause, andropause or malemenopause) syndrome, women's generation climacteric syndrome.Male PADAM and Women all are because of due to free serum gonadal hormone (testosterone or estrogen) level descends significantly.Old people's free serum gonadal hormone (testosterone or estrogen) level drops to due to the three big reasons significantly: the secretion of (1) gonadal hormone after 50 years old obviously descends, and especially reaches floor level in 70 years old later on; (2) serum sex hormone binding protein (SHBG) level progressively increased with the age, Zong cause the fall of the fall of free gonadal hormone greater than testosterone; (3) old people's liver CYP450 enzyme is significantly higher than young and middle-aged people, causes gonadal hormone catabolism to be strengthened, and has strengthened the fall of free gonadal hormone.
At present, male PADAM and Women mainly adopt the gonadal hormone alternative medicine.The gonadal hormone alternative medicine has the defective of itself: treatment may cause erythrocytosis and sleep apnea syndrome as testosterone, and this old man to the heart reservation function reduction can cause damage.Report is arranged, and testosterone increases benign prostatic hyperplasia (benign prostatic hyperplasia) and risk of prostate cancer; Estrin treatment significantly increases the sickness rate of women's heart disease, apoplexy, blood clot and breast carcinoma.Even more serious is to adopt the gonadal hormone alternative medicine in early days at male PADAM and Women, will speed up the dysregulation of hypothalamic pituitary gonadal axis, causes vicious cycle.
The technology contents of invention:
The present invention aims to provide the medicine with activity of fighting against senium, for male PADAM and Women provide a kind of safer effective Therapeutic Method in early days.Such has the low polarity ginsenoside of the medicine of activity of fighting against senium for one or more sugar based on 20 carbon, activity with the degraded of antagonism gonadal hormone, raising gonadal hormone blood plasma level, the hormone that is promoted is brought into play direct anti-aging effects on the one hand, form the vicious cycle of negative feedback blocking-up hypothalamic pituitary gonadal axis dysregulation on the one hand, thereby bring into play antidotal effect.
Described low polarity ginsenoside comprises one or more of the low polarity ginsenoside that lists in the table 1:
Table 1 has the low polarity ginsenoside of activity of fighting against senium
| Grouping | Low polarity ginsenoside |
| The triol group | I PPT II PT，Δ 20(21)-PPT，Δ 20(22)-PPT III 20-(R)-Rg 2，20-(S)-Rg 2，20-(R)-Rh 1，20-(S)-Rh 1 IV Rg 6、Rk 3、Rs 7，F 4、Rh 4、Rs 6 |
| The glycol group | I PPD II PD，Δ 20(21)-PPD，Δ 20(22)-PPD III 20-(R)-Rg 3、20-(S)-Rg 3、20-(R)-Rh 2And 20-(S)-Rh 2 IV Rk 1，Rk 2，Rs 5，Rg 5，Rh 3，Rs 4 |
Its chemical structural formula is:
| Ginsenoside | R | R’ | R” | |
| Diol type Triol type | (20S)Rb 1 (20S)Rb 2 (20S)Rb 3 (20S)Rc (20S)Rd (20S，R)Rg 3 (20S，R)Rh 2 (20S，R)Rs 3 C-K C-Y Mx Mc PPD (20S)Re (20S)Rg 1 (20S，R)Rg 2 (20S)Rf (20S，R)Rh 1 PPT | O-Glc 2- 1Glc O-Glc 2- 1Glc O-Glc 2- 1Glc O-Glc 2- 1Glc O-Glc 2- 1Glc O-Glc 2- 1Glc O-Glc O-Glc 2- 1Glc-Ac OH OH OH OH OH OH OH OH OH OH OH | H H H H H H H H H H H H H O-Glc 2- 1Rha O-Glc O-Glc 2- 1Rha O-Glc 2- 1Glc O-Glc OH | O-Glc 6- 1Glc O-Glc 6- 1Arap O-Glc 6- 1Xyl O-Glc 6- 1Araf O-Glc OH OH OH O-Glc O-Glc 6- 1Arap O-Glc 6- 1Xyl O-Glc 6- 1Araf OH O-Glc O-Glc OH O-Glc OH OH |
Glc：β-D-glucopyranosyl；Arap：α-L-arabinopyranosyl；
Xyl：β-D-xylopyranosyl；Araf：α-D-arabinofuranosyl；
Rha：-L-rhamnopyranosyl；Ac：6’-O-Acetyl.
| Ginsenoside | R | R’ | Ginsenoside | R | R’ | |
| Diol Type Triol Type | Rg 5 Rh 3 Rs 4 Δ 20(22)-PPD F 4 Rh 4 Rs 6 Δ 20(22)-PPT | O-Glc 2- 1Glc O-Glc O-Glc 2- 1Glc-Ac OH OH OH | H H H O-Glc 2- 1Rha O-Glc O-Glc-Ac | Rk 1 Rk 2 Rs 5 Δ 20(21)-PPD Rg 6 Rk 3 Rs 7 Δ 20(21)-PPT | O-Glc 2- 1Glc O-Glc O-Glc 2- 1Glc-Ac OH OH OH | H H H O-Glc 2- 1Rha O-Glc O-Glc-Ac |
The present invention has in the medicine of activity of fighting against senium, and the gastric acid after precursor compound that described low polarity ginsenoside can be natural or chemosynthesis or derivant process are oral is or/and intestinal etc. transform the back generation.
The present invention has in the medicine of activity of fighting against senium, and anti-aging effects can realize that dosage is counted 1-50mg/Kg/ days with total low polarity ginsenoside by using one or more low polarity ginsenosides.
The present invention has in the medicine of activity of fighting against senium, and low polarity ginsenoside can make the preparation of various pharmaceutical dosage forms with any officinal with compounding ingredient and excipient.
The present invention has in the medicine of activity of fighting against senium, low polarity ginsenoside can use separately, also can make compound preparation with the medicine (as testosterone 5 alpha reductase inhibitors) that is used for antidotal hormones (as testosterone or estrogen) and inhibition prostatic hyperplasia in the market.
The present invention has in the medicine of activity of fighting against senium, and described dosage form is any of oral, injection or local application's dosage form.
The present invention has in the medicine of activity of fighting against senium, and peroral dosage form can be tablet, powder, suspension, emulsion, capsule, granule, coated tablet, pill, liquid, spirit, syrup or limonada etc.
The present invention has in the medicine of activity of fighting against senium, and injection type can be water preparation, suspension or liposome solutions etc.
The present invention has in the medicine of activity of fighting against senium, and local application's dosage form can be ointment, solid, suspension, water preparation, spirit, powder, paste, suppository, aerosol, paste, liniment, lotion, enema or Emulsion etc.
The present invention has in the medicine of activity of fighting against senium, excipient can be one or more in following: (a) the powdery excipient of peroral dosage form such as lactose, crystalline cellulose, starch, dextrin, calcium phosphate, calcium carbonate, synthetic or natural aluminium dioxide, exsiccant aluminium hydroxide, magnesium stearate, sodium bicarbonate and surfactant such as phospholipid, cholic acid, Cremorphor, polysorbate (Tween) 80, Pluronic L64 and poloxamor etc.; (b) the powdery excipient of local application's dosage form such as zinc oxide, Talcum, starch, high potter's clay, borate powder, zinc stearate, magnesium stearate, magnesium carbonate, winnofil, bismuth subgallate, aluminum potassium sulfate powder and surfactant such as phospholipid, cholic acid, Cremorphor, polysorbate (Tween) 80, PluronicL64 and poloxamor or the like; (c) liquid usefulness excipient such as water, glycerol, propylene glycol, sweet taste syrup, ethanol, fatty oil, Ethylene Glycol, Polyethylene Glycol, sorbitol; The ointment excipient, as mixing-in fat, fatty oil, lanoline, vaseline, glycerol, wax, Japan wax, paraffin, sulphuric acid paraffin, resin, higher alcohol, plastics, ethylene glycol, water or surfactant (comprise liposoluble base, water-soluble base and the base that suspends, as with surfactant such as phospholipid, cholic acid, Cremorphor, polysorbate (Tween) 80, Pluronic L64 and poloxamor) etc.
Low polarity ginsenoside provided by the present invention, its CYP 450 enzymatic activitys suppress to be characterised in that:
(1) only has that the low polarity Radix Ginseng soap barrack furniture of sugar based has inhibitory action on 20 carbon;
(2) inhibition strength and glycosyl quantity are inversely proportional to;
(3) triol type ginsenoside's inhibitory action is greater than the diol type ginsenoside.
The antidotal effective ingredient and the defying age mechanism thereof of Radix Ginseng that the present invention is clear and definite provides the low polarity ginsenoside with activity of fighting against senium, for male PADAM and Women provide a kind of safer effective Therapeutic Method in early days.Such low polarity ginsenoside has the degraded of antagonism gonadal hormone, improves the activity of gonadal hormone blood plasma level, thereby brings into play antidotal effect.
The specific embodiment:
Embodiment 1 Protopanaxatriol is to serum androgen level affects
A), method: with the male mice is laboratory animal, the animal model of stress method making the low-level testosterone of blood plasma with suspention, vein gives various dose PPT, and testosterone concentration is to investigate the influence of chemical compound to androgen level in the serum in the radioimmunoassay detection serum.
B), experimental result: as shown in table 2:
Table 2.PPT is to the influence of level of serum testosterone
| Group | n | Testosterone concentration in the serum (pmol/L) |
| The low-level testosterone group of normal control group PPT 5mg/kg PPT 10mg/kg PPT 20mg/kg | 12 10 12 11 12 | 3341.1±1182.2 ** 1130.2±414.8 ## 1457.2±662.6 ## 2349.1±975.3 #，* 3058.2±987.6 ** |
#: with matched group ratio, P＜0.05; ##: with matched group ratio, P＜0.01
*: with low-level testosterone group ratio, P＜0.05;
*: with low-level testosterone group ratio, P＜0.01
The result shows that PPT can significantly improve testosterone levels in the blood, and improves the standard and be directly proportional with dosage.
Embodiment 2 each prescription are to the serum androgen level affects
A), method: with the male mice is laboratory animal, the animal model of stress method making the low-level testosterone of blood plasma with suspention, give the different prescriptions of ginsenoside and testosterone, testosterone concentration is to investigate the influence of chemical compound to sex hormone level in the serum in the radioimmunoassay detection serum.
B), experimental result: as shown in table 3:
Each prescription of table 3. is to the influence of level of serum testosterone
| Group | n | Testosterone concentration in the serum (pmol/L) |
| The low-level testosterone group of normal control group PPT 20mg/kg testosterone 5mg/kg | 12 10 12 12 | 3341.1±1182.2 ** 1130.2±414.8 ## 3058.2±987.6 ** 2131.4±848.6 ##，** |
| PPT 10mg/kg+ testosterone 5mg/kg PT 20mg/kg Rh 1 20mg/kg Rh 2 20mg/kg Rg 2 20mg/kg PD 20mg/kg PPD 20mg/kg F 4 20mg/kg RK 1 20mg/kg Rb 1，Rb 2, the prescription of Rc (2: 2: 1) 20mg/kg | 11 12 12 11 12 12 12 11 12 11 | 2844.3±1025.1 ** 2451.6±978.2 #，** 2113.5±691.1 ##，* 2071.2±775.2 ##，* 1964.8±579.4 ##，* 2295.1±814.4 ##，** 2746.2±1010.3 ** 1691.7±439.7 ##，* 1624.4±516.3 ##，* 1304.5±496.8 ## |
#: with matched group ratio, P＜0.05; ##: with matched group ratio, P＜0.01
*: with low-level testosterone group ratio, P＜0.05;
*: with low-level testosterone group ratio, P＜0.01
The result shows, the multiple rudimentary property ginsenoside of intravenously administrable can the antagonism male hormone metabolism, improve the androgen blood plasma level, and its effect is PPT＞PPD＞PT＞PD＞Rh in proper order
1＞Rh
2＞Rg
2＞F
4＞RK
1And natural ginseng saponin Rb
1, Rb
2, Rc is that main prescription does not have this activity.
Embodiment 3 Protopanaxatriols influence the serum estrogen level
A), method: with the female mice is laboratory animal, make the low-level estrogenic animal model of blood plasma with the removal ovary method, vein gives various dose PPT, and estradiol and progesterone concentration are to investigate the influence of chemical compound to estrogen level in the serum in the radioimmunoassay detection serum.
B), experimental result: as shown in table 4:
Table 4.PPT is to the influence of serum estrogen level
| Group | n | Estradiol concentration in the serum (pg/ml) | Progesterone concentration (ng/ml) in the serum |
| Normal control group castration group PPT 5mg/kg PPT 10mg/kg PPT 20mg/kg | 12 12 12 11 12 | 44.9±3.2 ** ＜20 ## ＜20 ## 24.3±1.9 ##，* 39.7±2.4 ** | 5.9±1.2 ** 1.5±0.2 ## 1.9±0.6 ## 3.8±1.0 #，* 5.5±3.2 ** |
#: with matched group ratio, P＜0.05; ##: with matched group ratio, P＜0.01
*: with castration group ratio, P＜0.05;
*: with castration group ratio, P＜0.01
The result shows that PPT can significantly improve estradiol and progesterone level in the blood, and improves the standard and be directly proportional with dosage.
Embodiment 4 each prescription influence the serum estrogen level
A), method: with the female mice is laboratory animal, make the low-level estrogenic animal model of blood plasma with the removal ovary method, give the different prescriptions of ginsenoside and estradiol, estradiol and progesterone concentration are to investigate the influence of chemical compound to estrogen level in the serum in the radioimmunoassay detection serum.
B), experimental result: as shown in table 5:
Each prescription of table 5. is to the influence of serum estrogen level
| Group | n | Estradiol concentration in the serum (pg/ml) | Progesterone concentration (ng/ml) in the serum |
| Normal control group castration group PPT 20mg/kg estradiol 0.5mg/kg PPT 10mg/kg+ estradiol 0.5mg/kg PT 20mg/kg Rh1 20mg/kg Rh 2 20mg/kg Rg 2 20mg/kg PD 20mg/kg PPD 20mg/kg F 4 20mg/kg RK 1 20mg/kg Rb 1，Rb 2, the prescription of Rc (2: 2: 1) 20mg/kg | 12 12 12 12 12 12 11 12 12 12 12 11 12 12 | 44.9±3.2 ** ＜20 ## 39.7±2.4 ** 28.6±1.8 ##，* 37.4±3.6 #，** 29.9±2.5 ##，* 25.4±2.1 ##，* 26.8±2.1 ##，* 22.1±1.7 ##，* 30.4±2.5 ##，* 37.5±3.1 ** ＜20 ## ＜20 ## ＜20 ## | 5.9±1.2 ** 1.5±0.2 ## 5.5±3.2 ** 3.8±1.4 #，* 5.2±2.7 ** 4.2±1.5 #，* 2.3±0.8 ## 2.6±1.0 ## 1.9±0.2 ## 4.4±1.9 #，* 5.3±2.8 ** 1.9±0.4 ## 1.7±0.2 ## 1.7±0.3 ## |
#: with matched group ratio, P＜0.05; ##: with matched group ratio, P＜0.01
*: with castration group ratio, P＜0.05;
*: with castration group ratio, P＜0.01
The result shows, the multiple rudimentary property ginsenoside of intravenously administrable can the antagonism estrogen metabolism, improve the estrogen blood plasma level, and its effect is PPT＞PPD＞PD＞PT＞Rh in proper order
2＞Rh
1＞Rg
2＞F
4＞RK
1And natural ginseng saponin Rb
1, Rb
2, Rc is that main prescription does not have this activity.
It is active that embodiment 5CYP450 suppresses
A), method: be experimental system with rat liver microsomes, people's hepatomicrosome and recombined human CYP3A4 respectively, the activity of indicating CYP3A with testosterone 6 beta-hydroxy reactions, (S-Rg3 is 1 μ M to add 100 μ M ginsenosides, PT and PPT are 20 μ M) detect it to the active inhibition of CYP3A, the special inhibitor ketoconazole (KTZ) of CYP3A is as positive control, 37 ℃ were reacted 10 minutes, and HPLC detects.
B), experimental result: as shown in table 6.
Table 6. ginsenoside is to the inhibitory action of CYP3A
| CYP3A activity (%) | |||
| Rat liver microsomes | People's hepatomicrosome | Recombined human CYP3A4 | |
| Control group Rb1 Rb2 Rc Rd R-Rg3 S-Rg3 Rh2 C-K PPD Re Rg1 Rg2 Rh1 PT PPT | 100.0±1.7 104.9±1.0 89.0±1.8 93.7±1.3 86.3±3.0 102.9±1.2 8.6±1.1 * 53.5±1.4 * 107.0±2.8 31.6±2.0 * 95.9±1.5 96.4±5.0 70.6±7.2 * 62.0±2.3 * 14.2±1.0 * 19.4±3.1 * | 100.0±2.5 106.0±2.9 90.6±2.6 92.9±4.1 41.2±1.6 * 104.1±2.1 10.1±3.4 * 42.8±4.5 * 105.0±4.4 13.8±1.8 * 105.0±1.1 99.7±1.3 75.5±5.3 * 37.2±4.3 * 31.2±1.5 * 9.0±1.7 * | 100.0±3.6 117.9±2.0 * 101.7±7.2 107.5±2.5 24.4±1.0 * 101.2±1.6 17.7±2.9 * 22.5±1.0 * 98.1±4.1 36.5±1.0 * 110.6±5.6 111.1±4.0 9.9±1.9 * 38.4±1.6 * 7.8±1.8 * 20.1±1.4 * |
| F 4 RK 1 KTZ | 87.1±2.9 91.2±3.2 39.9±0.8 * | 80.2±1.6 * 82.1±2.3 * 5.3±1.1 * | 72.4±2.0 * 85.5±2.1 * 9.5±1.6 * |
*: with matched group ratio, P＜0.01
The result shows, ginsenoside Rd, S-Rg
3, Rh
2, PPD, Rg
2, Rh
1, PT, PPT, F
4, RK
1CYP3A there is inhibitory action.
Claims (10)
1, a kind of medicine with activity of fighting against senium is characterized in that: described medicine is the low polarity ginsenoside of one or more sugar based on 20 carbon, has the activity of the degraded of antagonism gonadal hormone, raising gonadal hormone blood plasma level.
2, according to the described medicine with activity of fighting against senium of claim 1, it is characterized in that: described low polarity ginsenoside comprises one or more of following low polarity ginsenoside:
(1) triol type ginsenoside aglycon
The Protopanaxatriol (protopanaxatriol, PPT);
(2) triol type ginsenoside aglycone derivative
The panaxatriol (panaxatriol, PT);
3 β, 6 α, 12 β-three hydroxyl-20 (21), 24 (25)-diene-dammarane [dammar-3 β, 6 α, 12 β-trihydroxyl-20 (21), 24 (25)-diene are called for short Δ
20 (21)-PPT];
3 β, 6 α, 12 β-three hydroxyl-20 (22), 24 (25)-diene-dammarane [dammar-3 β, 6 α, 12 β-trihydroxyl-20 (22), 24 (25)-diene are called for short Δ
20 (22)-PPT];
(3) 20 the free triol type of hydroxyl ginsenosides
20-(R)-Rg
2, 20-(S)-Rg
2, 20-(R)-Rh
1And 20-(S)-Rh
1
The triol type ginsenoside of (4) 20 ethylene linkages
Δ
20 (21)-triol type ginsenoside: Rg
6, Rk
3, Rs
7
Δ
20 (22)-triol type ginsenoside: F
4, Rh
4, Rs
6
(5) diol type ginsenoside aglycon
Protopanoxadiol (protopanaxadiol, PPD);
(6) diol type ginsenoside aglycone derivative
The panoxadiol (panaxadiol, PD);
3 β, [24 (25)-diene are called for short Δ to 12 β-dihydroxy-20 (21), 24 (25)-diene-dammarane for dammar-3 β, 12 β-dihydroxyl-20 (21)
20 (21)-PPD];
3 β, [24 (25)-diene are called for short Δ to 12 β-dihydroxy-20 (22), 24 (25)-diene-dammarane for dammar-3 β, 12 β-dihydroxyl-20 (22)
20 (22)-PPD];
(7) 20 free diol type ginsenosides of hydroxyl
Ginsenoside 20-(R)-Rg
3, 20-(S)-Rg
3, 20-(R)-Rh
2And 20-(S)-Rh
2
The diol type ginsenoside of (8) 20 ethylene linkages
Δ
20 (21)-diol type ginsenoside: Rk
1, Rk
2, Rs
5
Δ
20 (22)-diol type ginsenoside: Rg
5, Rh
3, Rs
4
3, according to claim 1 and 2 described medicines, it is characterized in that with activity of fighting against senium: described low polarity ginsenoside be natural or the precursor compound of chemosynthesis or derivant through oral back at gastric acid or/and transform under the intestinal effect and to produce.
4, according to claim 1 and 2 described medicines with activity of fighting against senium, it is characterized in that: described low polarity ginsenoside, dosage is counted 1-50mg/Kg/ days with total low polarity ginsenoside.
5, according to claim 1 and 2 described medicines with activity of fighting against senium, it is characterized in that: described low polarity ginsenoside and any officinal are made the preparation of various pharmaceutical dosage forms with compounding ingredient and excipient.
6, according to the described medicine with activity of fighting against senium of claim 5, it is characterized in that: described low polarity ginsenoside makes compound preparation with the medicine that is used for antidotal hormones and inhibition prostatic hyperplasia in the market.
7, according to the described medicine with activity of fighting against senium of claim 6, it is characterized in that: described dosage form is any of oral, injection or local application's dosage form.
8, according to the described medicine with activity of fighting against senium of claim 6, it is characterized in that: described peroral dosage form comprises tablet, powder, suspension, emulsion, capsule, granule, coated tablet, pill, liquid, spirit, syrup, limonada.
9, according to the described medicine with activity of fighting against senium of claim 6, it is characterized in that: described injection type comprises water preparation, suspension, liposome solutions.
10, according to the described medicine with activity of fighting against senium of claim 6, it is characterized in that: described local application dosage form comprises ointment, solid, suspension, water preparation, spirit, powder, paste, suppository, aerosol, paste, liniment, lotion, enema, Emulsion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2004101004542A CN1795868A (en) | 2004-12-23 | 2004-12-23 | Medication possessing activity of fighting against senium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2004101004542A CN1795868A (en) | 2004-12-23 | 2004-12-23 | Medication possessing activity of fighting against senium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1795868A true CN1795868A (en) | 2006-07-05 |
Family
ID=36817323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004101004542A Pending CN1795868A (en) | 2004-12-23 | 2004-12-23 | Medication possessing activity of fighting against senium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1795868A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008110050A1 (en) * | 2007-03-12 | 2008-09-18 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | THE USE OF GINSENOSIDE Rg1, ITS METABOLITES GINSENOSIDE Rh1 AND PpT |
| CN102481303A (en) * | 2009-06-30 | 2012-05-30 | 狮王株式会社 | Glucose metabolism-improving agent and glucose metabolism-improving composition |
| CN103239398A (en) * | 2012-02-02 | 2013-08-14 | 天马药业(集团)股份有限公司 | Dammarane sapogenin suspension, and preparation method and application thereof |
| WO2015069086A1 (en) * | 2013-11-11 | 2015-05-14 | 서울대학교산학협력단 | Composition containing fraction of panax ginseng or ginsenoside separated therefrom for preventing or treating disease treated by activation of sirtuins |
| CN109689020A (en) * | 2016-09-08 | 2019-04-26 | 株式会社爱茉莉太平洋 | For skin anti-aging, composition comprising dehydroabietic acid and compound K |
| US11633413B2 (en) | 2019-09-27 | 2023-04-25 | Amorepacific Corporation | Composition for preventing or improving menopausal symptom comprising novel ginsenoside |
-
2004
- 2004-12-23 CN CNA2004101004542A patent/CN1795868A/en active Pending
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8765695B2 (en) | 2007-03-12 | 2014-07-01 | Jecui Health Industry Corp. Ltd. | Use of ginsenoside RG1, its metabolites ginsenoside RH1 and/or PPT |
| JP2010520894A (en) * | 2007-03-12 | 2010-06-17 | インスティテュート オブ マテリア メディカ， チャイニーズ アカデミー オブ メディカル サイエンスィズ | Use of ginsenoside Rg1, its metabolite ginsenoside Rh1 and / or Ppt |
| WO2008110050A1 (en) * | 2007-03-12 | 2008-09-18 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | THE USE OF GINSENOSIDE Rg1, ITS METABOLITES GINSENOSIDE Rh1 AND PpT |
| JP2013256519A (en) * | 2007-03-12 | 2013-12-26 | Inst Of Materia Medica Chinese Academy Of Medical Sciences | USE OF GINSENOSIDE Rg1, ITS METABOLITES GINSENOSIDE Rh1 AND/OR Ppt |
| CN102481303A (en) * | 2009-06-30 | 2012-05-30 | 狮王株式会社 | Glucose metabolism-improving agent and glucose metabolism-improving composition |
| CN102481303B (en) * | 2009-06-30 | 2013-08-14 | 狮王株式会社 | Glucose metabolism-improving agent and glucose metabolism-improving composition |
| CN103239398A (en) * | 2012-02-02 | 2013-08-14 | 天马药业(集团)股份有限公司 | Dammarane sapogenin suspension, and preparation method and application thereof |
| CN103239398B (en) * | 2012-02-02 | 2014-07-16 | 天马药业(集团)股份有限公司 | Dammarane sapogenin suspension, and preparation method and application thereof |
| WO2015069086A1 (en) * | 2013-11-11 | 2015-05-14 | 서울대학교산학협력단 | Composition containing fraction of panax ginseng or ginsenoside separated therefrom for preventing or treating disease treated by activation of sirtuins |
| KR101548605B1 (en) * | 2013-11-11 | 2015-09-01 | 서울대학교산학협력단 | Compositions comprising fractions of Panax ginseng or ginsenosides isolated therefrom for prevention or treatment of disease through activation of sirtuins |
| CN109689020A (en) * | 2016-09-08 | 2019-04-26 | 株式会社爱茉莉太平洋 | For skin anti-aging, composition comprising dehydroabietic acid and compound K |
| CN109689020B (en) * | 2016-09-08 | 2022-06-21 | 株式会社爱茉莉太平洋 | Composition containing dehydroabietic acid and compound K for resisting skin aging |
| US11633413B2 (en) | 2019-09-27 | 2023-04-25 | Amorepacific Corporation | Composition for preventing or improving menopausal symptom comprising novel ginsenoside |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1239160C (en) | Hormone replacement therapy | |
| CN1182433A (en) | Metabolites of ginseng saponins by human intestinal bacteria and its preparation for anticancer | |
| Kang et al. | Gut microbiota in the pharmacokinetics and colonic deglycosylation metabolism of ginsenoside Rb1 in rats: Contrary effects of antimicrobials treatment and restraint stress | |
| JP2008536879A (en) | Drug or nutrition combination preparation and preparation, method for improving absorption by internal use, and application method thereof | |
| CN1795868A (en) | Medication possessing activity of fighting against senium | |
| WO2020051973A1 (en) | Application of terra flava usta in preparation of medicaments for preventing and treating allergic diseases, mental diseases, metabolic diseases, and endocrine disorders | |
| Kazerooni et al. | Short-term metformin treatment for clomiphene citrate–resistant women with polycystic ovary syndrome | |
| CN1785292A (en) | Medicine for treating flooding and spotting and its preparation method | |
| Scharbo-Dehaan | Hormone replacement therapy | |
| CN105233300A (en) | Stable vildagliptin composition and preparation method thereof | |
| CN101099724A (en) | Micronization femara and its composition | |
| CN114209739A (en) | Application of pulsatilla chinensis extract in preparation of antidepressant drug | |
| CN1843399A (en) | Medicine for treating benign prostate hyperplasia and its preparation process | |
| CN107349210B (en) | Compositions having synergistic alpha-amylase inhibitory activity | |
| CN1264533C (en) | Radix salvia miltiorrhiza capsule compound and method for preparing same | |
| CN1155380C (en) | Application of sophocarpidine oxide in preparing medicine to treat ulcerative colitis | |
| CN1846775A (en) | New medicinal use of Chinese medicine nutmeg and its extract | |
| CN1468602A (en) | Application of naringin in preparing medicine for supporting treatment of SARS | |
| CN1305479C (en) | Low polarity ginsenoside combination possessing anti-tumor activity | |
| CN1596900A (en) | Rusco saponin element and application of its saponin in preparation of medicine preventing and treating embolus disease | |
| CN113304157B (en) | Active composition for treating polycystic ovarian syndrome (PCOS) | |
| CN1839956A (en) | Pharmaceutical composition containing curcumin and its formulation | |
| CN1839869A (en) | Use of molo glycoside in alpha-glucosaccharase inhibitor | |
| CN116236526B (en) | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method thereof | |
| CN1903281A (en) | Traditional Chinese medicine composition for treating urinary system infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |